LENZ Therapeutics (LENZ) Projected to Post Quarterly Earnings on Wednesday

LENZ Therapeutics (NASDAQ:LENZ) will likely be posting its quarterly earnings results before the market opens on Wednesday, February 5th. Analysts expect LENZ Therapeutics to post earnings of ($0.41) per share for the quarter.

LENZ Therapeutics (NASDAQ:LENZ) last announced its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.09. During the same quarter in the prior year, the business posted ($1.33) earnings per share. On average, analysts expect LENZ Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

LENZ Therapeutics Trading Down 0.6 %

Shares of LENZ opened at $25.37 on Tuesday. LENZ Therapeutics has a 52-week low of $14.42 and a 52-week high of $38.93. The firm has a 50-day moving average price of $29.49 and a 200 day moving average price of $26.81.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $38.00 target price on shares of LENZ Therapeutics in a report on Thursday, November 7th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $35.40.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.